Crossing lung barriers: inhalable biomaterials for lung cancer from design to application.

Authors

Wei Zhang, Rui Feng, Cheng Cao

Published in

Nanoscale. Sep 28, 2026. Epub Sep 28, 2026.

Abstract

Lung cancer remains the leading cause of cancer death worldwide. Systemic drug delivery often results in low lung accumulation and high toxicity. Inhalable biomaterials offer a promising alternative by delivering therapeutics directly to lung lesions, enabling high local concentrations and minimal systemic exposure. This review systematically summarizes recent advances in inhalable bio-nanomaterials for lung cancer therapy. We first analyze key pulmonary barriers-mucus, surfactant, alveolar-capillary barrier, and macrophage clearance-and then outline material design strategies based on particle size, morphology, and surface engineering. The review highlights progress in inhaled immunomodulation (tumor vaccines and immune checkpoint modulation) and combination therapies (chemotherapy, physical fields, ferroptosis, and radiotherapy). Finally, we discuss device compatibility and clinical translation challenges. This review provides a practical reference for developing inhalable biomaterials toward precision lung cancer treatment.

PMID:
42803322
Bibliographic data and abstract were imported from PubMed on 28 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.